Episodic Paroxysmal hemicrania. Episodic paroxysmal hemicrania
Conditions
Interventions
Intervention group: Cyproheptadine 0.2 to 0.4 mg per kg bodyweight of the child is given in two divided doses for the child. Cyproheptadine is available in the form of 4 mg tablets and 2 mg syrup in 5
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
2 Years to 15 Years
Inclusion criteria
Inclusion criteria: Children with 2 to 15 years of age Children with episodic paroxysmal hemicrania referred to neurology clinic whose disease has been definitively diagnosed according to the ICHD criteria. Number of attacks of equal or more than once a week
Exclusion criteria
Exclusion criteria: Patients' unwillingness to cooperate during the study Severe and uncontrollable side effects of cyproheptadine If, based on possible laboratory or imaging findings, a diagnosis other than episodic paroxysmal hemicrania is made during the study Epilepsy or epileptic headaches Existence of structural anomalies in MRI imaging History of allergies to similar drugs Inability to record data on the number, duration, and severity of headaches Taking a prophylactic drug other than Cyproheptadine Severe psychiatric problems such as depression or ADHD
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency, duration, and severity of headache attacks and drug side effects. Timepoint: before intervention and each month after intervention. Method of measurement: Checklist includes measuring the number of attacks per week, the duration of attacks in form of minutes and its severity according to the VAS criteria and the occurrence of known side effects. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactJafar Nasiri
Esfahan University of Medical Sciences
Outcome results
None listed